Background: Although low alanine aminotransferase (ALT) levels have been associated with poor outcomes in the elderly population, the determinants subtending this association have been poorly explored. To gain insight into this topic, we analyzed data from a prospective population-based database (InCHIANTI study) in which frailty, disability, sarcopenia, and pyridoxine levels were systematically assessed. Methods: Data are from 765 participants aged more than 65 years (mean age 75.3 years, women 61.8%), without chronic liver disease, malignancies, or alcohol abuse. Frailty was defined according to Fried criteria, sarcopenia through peripheral Quantitative-Computed-Tomography (lowest gender-specific tertile of the residuals of a linear regression of muscle mass from height and fat mass), and disability as self-reported need for help in at least one basic daily living activity. Associations of ALT with overall and cardiovascular mortality were assessed by Cox-models with time-dependent covariates. Results: ALT activity was inversely associated with frailty, sarcopenia, disability, and pyridoxine deficiency; however, higher ALT was confirmed to be protective with respect of overall and cardiovascular mortality even in multiple-adjusted models including all these covariates (overall: hazard ratio [HR] 0.98 [0.96-1], p = .02; cardiovascular: 0.94 [0.9-0.98], p < .01). The association between ALT activity and mortality was nonlinear (J-shaped), and subjects in the lower quintiles of ALT levels showed a sharply increased overall and cardiovascular mortality. Conclusions: These results suggest that reduced ALT levels in older individuals can be considered as a marker of frailty, disability, and sarcopenia, and as an independent predictor of adverse outcomes. The possible relationship between reduced ALT and impaired hepatic metabolic functions should be explored.
Background: Although low alanine aminotransferase (ALT) levels have been associated with poor outcomes in the elderly population, the determinants subtending this association have been poorly explored. To gain insight into this topic, we analyzed data from a prospective population-based database (InCHIANTI study) in which frailty, disability, sarcopenia, and pyridoxine levels were systematically assessed. Methods: Data are from 765 participants aged more than 65 years (mean age 75.3 years, women 61.8%), without chronic liver disease, malignancies, or alcohol abuse. Frailty was defined according to Fried criteria, sarcopenia through peripheral Quantitative-Computed-Tomography (lowest gender-specific tertile of the residuals of a linear regression of muscle mass from height and fat mass), and disability as self-reported need for help in at least one basic daily living activity. Associations of ALT with overall and cardiovascular mortality were assessed by Cox-models with time-dependent covariates. Results: ALT activity was inversely associated with frailty, sarcopenia, disability, and pyridoxine deficiency; however, higher ALT was confirmed to be protective with respect of overall and cardiovascular mortality even in multiple-adjusted models including all these covariates (overall: hazard ratio [HR] 0.98 [0.96-1], p = .02; cardiovascular: 0.94 [0.9-0.98], p < .01). The association between ALT activity and mortality was nonlinear (J-shaped), and subjects in the lower quintiles of ALT levels showed a sharply increased overall and cardiovascular mortality. Conclusions: These results suggest that reduced ALT levels in older individuals can be considered as a marker of frailty, disability, and sarcopenia, and as an independent predictor of adverse outcomes. The possible relationship between reduced ALT and impaired hepatic metabolic functions should be explored.
Authors: Roger K Schindhelm; Jacqueline M Dekker; Giel Nijpels; Lex M Bouter; Coen D A Stehouwer; Robert J Heine; Michaela Diamant Journal: Atherosclerosis Date: 2006-05-08 Impact factor: 5.162
Authors: Eran Elinav; Iddo Z Ben-Dov; Elizabeth Ackerman; Alexander Kiderman; Frida Glikberg; Yami Shapira; Zvi Ackerman Journal: Am J Gastroenterol Date: 2005-10 Impact factor: 10.864
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: E Ramaty; E Maor; N Peltz-Sinvani; A Brom; A Grinfeld; S Kivity; S Segev; Y Sidi; T Kessler; B A Sela; G Segal Journal: Eur J Intern Med Date: 2014-10-30 Impact factor: 4.487
Authors: Yifei Lu; James R Pike; Elizabeth Selvin; Thomas Mosley; Priya Palta; A Richey Sharrett; Alvin Thomas; Laura Loehr; A Sidney Barritt; Ron C Hoogeveen; Gerardo Heiss Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.160
Authors: Hilary M DuBrock; Michael J Krowka; Karen Krok; Kimberly Forde; Carl Mottram; Paul Scanlon; Nadine Al-Naamani; Mamta Patel; Amber McCormick; Michael B Fallon; Steven M Kawut Journal: Liver Transpl Date: 2020-07-09 Impact factor: 5.799
Authors: N Lasman; M Shalom; N Turpashvili; G Goldhaber; Y Lifshitz; E Leibowitz; G Berger; G Saltzman-Shenhav; A Brom; D Cohen; C Avaky; G Segal Journal: BMC Pulm Med Date: 2020-05-11 Impact factor: 3.317